VN
Vanda Pharmaceuticals Inc.
VNDA · NASDAQ
$5.15 +0.59% (+$0.03)
1M -2.09%
Market Cap $309.7M
P/E Ratio -
Div. Yield -
ROE 84.95%
Bulios Fair Price
$5.74
11.5% upside
Current Price
$5.15
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VNDA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
97 /100
Cheap P/S 1.44x
P/B 1.41x
P/E N/A
Growth
0 /100
Declining Rev. growth 5.29%
Book val. growth 14.70%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 92.82%
FCF margin 89.67%
Net margin 127.41%
Quality
7 /100
Poor ROIC 113.80%
Asset turnover 0.52x
ROE 84.95%
Debt
94 /100
Low Debt/Equity 0.10x
Current ratio 1.61x
Int. coverage N/A
Stability
45 /100
Moderate Beta 0.65x
Profitable years 0
Rev. volatility 17.67%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VNDA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Mihael H. Polymeropoulos
Employees
533
Headquarters
Washington
Upcoming events
04 NOV
Earnings
Upcoming earnings report